Antiphospholipid Syndrome

Hughes, 1993, The antiphospholipid syndrome: ten years on, Lancet, 342, 341, 10.1016/0140-6736(93)91477-4 Vila, 1994, Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects, Thromb Haemost, 72, 209, 10.1055/s-0038-1648840 Lim, 2013, Antiphospholipid syndrome, Hematology Am Soc Hematol Educ Program, 2013, 675, 10.1182/asheducation-2013.1.675 Miyakis, 2006, International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS), J Thromb Haemost, 4, 295, 10.1111/j.1538-7836.2006.01753.x Petri, 2000, Epidemiology of the antiphospholipid antibody syndrome, J Autoimmun, 15, 145, 10.1006/jaut.2000.0409 Olech, 2006, The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis, Curr Rheumatol Rep, 8, 100, 10.1007/s11926-006-0049-8 Mineo, 2013, Inhibition of nitric oxide and antiphospholipid antibody-mediated thrombosis, Curr Rheumatol Rep, 15, 324, 10.1007/s11926-013-0324-4 Soltész, 2007, Cardiac manifestations in antiphospholipid syndrome, Autoimmun Rev, 6, 379, 10.1016/j.autrev.2007.01.003 Cervera, 2015, Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients, Ann Rheum Dis, 74, 1011, 10.1136/annrheumdis-2013-204838 Ambrosino, 2014, Markers of cardiovascular risk in patients with antiphospholipid syndrome: a meta-analysis of literature studies, Ann Med, 46, 693, 10.3109/07853890.2014.959559 Amigo, 2006, Kidney disease in antiphospholipid syndrome, Rheum Dis Clin North Am, 32, 509, 10.1016/j.rdc.2006.05.004 Sciascia, 2014, Renal involvement in antiphospholipid syndrome, Nat Rev Nephrol, 10, 279, 10.1038/nrneph.2014.38 Asherson, 2003, Catastrophic antiphospholipid syndrome: international consensus statement on classification criteria and treatment guidelines, Lupus, 12, 530, 10.1191/0961203303lu394oa Blum, 2004, The antiphospholipid syndrome and endothelial function, Isr Med Assoc J, 6, 556 Agostinis, 2011, In vivo distribution of β2 glycoprotein I under various pathophysiologic conditions, Blood, 118, 4231, 10.1182/blood-2011-01-333617 Meroni, 2016, Anti-beta-2 glycoprotein I epitope specificity: from experimental models to diagnostic tools, Lupus, 25, 905, 10.1177/0961203316641772 Meroni, 2011, Pathogenesis of antiphospholipid syndrome: understanding the antibodies, Nat Rev Rheumatol, 7, 330, 10.1038/nrrheum.2011.52 Galli, 2003, Anti-β2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome, Blood, 102, 2717, 10.1182/blood-2002-11-3334 Miyakis, 2004, Beta 2 glycoprotein I—function in health and disease, Thromb Res, 114, 335, 10.1016/j.thromres.2004.07.017 Arad, 2011, β2-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model, Blood, 117, 3453, 10.1182/blood-2010-08-300715 Fischetti, 2005, Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor, Blood, 106, 2340, 10.1182/blood-2005-03-1319 Mulla, 2009, Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4/MyD88 pathway, Am J Reprod Immunol, 62, 96, 10.1111/j.1600-0897.2009.00717.x De Caterina, 1995, Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines, J Clin Invest, 96, 60, 10.1172/JCI118074 Palmer, 1987, Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor, Nature, 327, 524, 10.1038/327524a0 Radomski, 1987, Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium, Lancet, 2, 1057, 10.1016/S0140-6736(87)91481-4 Ames, 2010, Clinical relevance of nitric oxide metabolites and nitrative stress in thrombotic primary antiphospholipid syndrome, J Rheumatol, 37, 2523, 10.3899/jrheum.100494 Charakida, 2009, Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome, JAMA, 302, 1210, 10.1001/jama.2009.1346 Freedman, 1999, Deficient platelet-derived nitric oxide and enhanced hemostasis in mice lacking the NOSIII gene, Circ Res, 84, 1416, 10.1161/01.RES.84.12.1416 Atochin, 2007, The phosphorylation state of eNOS modulates vascular reactivity and outcome of cerebral ischemia in vivo, J Clin Invest, 117, 1961, 10.1172/JCI29877 Huang, 1996, Enlarged infarcts in endothelial nitric oxide synthase knockout mice are attenuated by nitro-L-arginine, J Cereb Blood Flow Metab, 16, 981, 10.1097/00004647-199609000-00023 Kuhlencordt, 2004, Role of endothelial nitric oxide synthase in endothelial activation: insights from eNOS knockout endothelial cells, Am J Physiol Cell Physiol, 286, C1195, 10.1152/ajpcell.00546.2002 Lefer, 1999, Leukocyte-endothelial cell interactions in nitric oxide synthase-deficient mice, Am J Physiol, 276, H1943 Freedman, 2008, Oxidative stress and platelets, Arterioscler Thromb Vasc Biol, 28, s11, 10.1161/ATVBAHA.107.159178 Freedman, 2003, Nitric oxide and its relationship to thrombotic disorders, J Thromb Haemost, 1, 1183, 10.1046/j.1538-7836.2003.00180.x Prasad, 2016, Coronary endothelial dysfunction is associated with increased risk of venous thromboembolism, Thromb Res, 139, 17, 10.1016/j.thromres.2015.12.024 Mineo, 2011, New insights into the molecular basis of the antiphospholipid syndrome, Drug Discov Today Dis Mech, 8, e47, 10.1016/j.ddmec.2011.12.002 Ramesh, 2011, Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2, J Clin Invest, 121, 120, 10.1172/JCI39828 de Groot, 2004, β2-Glycoprotein I and LDL-receptor family members, Thromb Res, 114, 455, 10.1016/j.thromres.2004.06.015 Ninivaggi, 2012, Conformation of beta2glycoprotein I and its effect on coagulation, Thromb Res, 130, S33, 10.1016/j.thromres.2012.08.269 Jankowski, 2003, Thrombogenicity of β2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster, Blood, 101, 157, 10.1182/blood-2002-05-1310 Pierangeli, 2008, Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms, Semin Thromb Hemost, 34, 236, 10.1055/s-0028-1082267 Pierangeli, 2004, Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies, Thromb Res, 114, 467, 10.1016/j.thromres.2004.06.031 Romay-Penabad, 2011, Apolipoprotein E receptor 2 is involved in the thrombotic complications in a murine model of the antiphospholipid syndrome, Blood, 117, 1408, 10.1182/blood-2010-07-299099 Urbanus, 2008, Platelet activation by dimeric β2-glycoprotein I requires signaling via both glycoprotein Ibα and apolipoprotein E receptor 2′, J Thromb Haemost, 6, 1405, 10.1111/j.1538-7836.2008.03021.x Greif, 2002, Site-specific dephosphorylation of endothelial nitric oxide synthase by protein phosphatase 2A: evidence for crosstalk between phosphorylation sites, Biochemistry, 41, 15845, 10.1021/bi026732g Michell, 2001, Coordinated control of endothelial nitric-oxide synthase phosphorylation by protein kinase C and the cAMP-dependent protein kinase, J Biol Chem, 276, 17625, 10.1074/jbc.C100122200 Der, 2007, Impaired endothelial function and increased carotid intima-media thickness in association with elevated von Willebrand antigen level in primary antiphospholipid syndrome, Lupus, 16, 497, 10.1177/0961203307080224 Medina, 2003, Increased carotid artery intima-media thickness may be associated with stroke in primary antiphospholipid syndrome, Ann Rheum Dis, 62, 607, 10.1136/ard.62.7.607 Alarcón-Segovia, 1989, Antiphospholipid arterial vasculopathy, J Rheumatol, 16, 762 Hughson, 1995, Spectrum of vascular pathology affecting patients with the antiphospholipid syndrome, Hum Pathol, 26, 716, 10.1016/0046-8177(95)90218-X Long, 2008, The role of antiphospholipid syndrome in cardiovascular disease, Hematol Oncol Clin North Am, 22, 79, 10.1016/j.hoc.2007.10.002 Hughson, 1993, Thrombotic cerebral arteriopathy in patients with the antiphospholipid syndrome, Mod Pathol, 6, 644 Westerman, 1992, Neuropathologic findings in multi-infarct dementia associated with anticardiolipin antibody. Evidence for endothelial injury as the primary event, Arthritis Rheum, 35, 1038, 10.1002/art.1780350908 Canaud, 2014, Inhibition of the mTORC pathway in the antiphospholipid syndrome, N Engl J Med, 371, 303, 10.1056/NEJMoa1312890 Canaud, 2015, AKT/mTORC pathway in antiphospholipid-related vasculopathy: a new player in the game, Lupus, 24, 227, 10.1177/0961203315569336 Gimbrone, 2013, Vascular endothelium, hemodynamics, and the pathobiology of atherosclerosis, Cardiovasc Pathol, 22, 9, 10.1016/j.carpath.2012.06.006 Gimbrone, 2016, Endothelial cell dysfunction and the pathobiology of atherosclerosis, Circ Res, 118, 620, 10.1161/CIRCRESAHA.115.306301 Stary, 2000, Natural history and histological classification of atherosclerotic lesions: an update, Arterioscler Thromb Vasc Biol, 20, 1177, 10.1161/01.ATV.20.5.1177 Virmani, 2000, Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions, Arterioscler Thromb Vasc Biol, 20, 1262, 10.1161/01.ATV.20.5.1262 Ames, 2009, Antiphospholipid antibodies and atherosclerosis: insights from systemic lupus erythematosus and primary antiphospholipid syndrome, Clin Rev Allergy Immunol, 37, 29, 10.1007/s12016-008-8099-5 Belizna, 2008, Early atheroma in primary and secondary antiphospholipid syndrome: an intrinsic finding, Semin Arthritis Rheum, 37, 373, 10.1016/j.semarthrit.2007.08.002 Cervera, 2009, The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe, Lupus, 18, 889, 10.1177/0961203309106832 Matsuura, 2000, Accelerated atheroma and anti-beta2-glycoprotein I antibodies, Lupus, 9, 210, 10.1191/096120300678828262 Petri, 2000, Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort, Lupus, 9, 170, 10.1191/096120300678828226 Shoenfeld, 2005, Accelerated atherosclerosis in autoimmune rheumatic diseases, Circulation, 112, 3337, 10.1161/CIRCULATIONAHA.104.507996 Vaarala, 1996, Antiphospholipid antibodies and atherosclerosis, Lupus, 5, 442, 10.1177/096120339600500522 Jara, 2003, Atherosclerosis and antiphospholipid syndrome, Clin Rev Allergy Immunol, 25, 79, 10.1385/CRIAI:25:1:79 Hasunuma, 1997, Involvement of β2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages, Clin Exp Immunol, 107, 569, 10.1046/j.1365-2249.1997.d01-948.x Kobayashi, 2001, A specific ligand for β2-glycoprotein I mediates autoantibody-dependent uptake of oxidized low density lipoprotein by macrophages, J Lipid Res, 42, 697, 10.1016/S0022-2275(20)31631-X Liu, 2002, ω-Carboxyl variants of 7-ketocholesteryl esters are ligands for β2-glycoprotein I and mediate antibody-dependent uptake of oxidized LDL by macrophages, J Lipid Res, 43, 1486, 10.1194/jlr.M20063-JLR200 Adler, 1995, The presence of antiphospholipid antibodies in acute myocardial infarction, Lupus, 4, 309, 10.1177/096120339500400413 Erkkilä, 2000, Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease, Arterioscler Thromb Vasc Biol, 20, 204, 10.1161/01.ATV.20.1.204 Erkkilä, 2005, Antibodies against oxidized LDL and cardiolipin and mortality in patients with coronary heart disease, Atherosclerosis, 183, 157, 10.1016/j.atherosclerosis.2005.02.026 Sherer, 2006, Mechanisms of disease: atherosclerosis in autoimmune diseases, Nat Clin Pract Rheumatol, 2, 99, 10.1038/ncprheum0092 Shoenfeld, 2000, Autoantibodies associated with atherosclerosis, Ann Med, 32, 37 Veres, 2004, Antiphospholipid antibodies in acute coronary syndrome, Lupus, 13, 423, 10.1191/0961203304lu1011oa Matsuo, 2013, Repeated episodes of thrombosis as a potential mechanism of plaque progression in cardiac allograft vasculopathy, Eur Heart J, 34, 2905, 10.1093/eurheartj/eht209 Sacré, 2010, Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study, Arthritis Rheum, 62, 2093 Padjas, 2016, Myocardial ischaemia, coronary atherosclerosis and pulmonary pressure elevation in antiphospholipid syndrome patients, Adv Clin Exp Med, 25, 1199, 10.17219/acem/63753 Urbanus, 2008, Platelets and the antiphospholipid syndrome, Lupus, 17, 888, 10.1177/0961203308096344 de Laat, 2011, Autoantibodies directed against domain I of beta2-glycoprotein I, Curr Rheumatol Rep, 13, 70, 10.1007/s11926-010-0144-8 de Laat, 2009, The association between circulating antibodies against domain I of beta2-glycoprotein I and thrombosis: an international multicenter study, J Thromb Haemost, 7, 1767, 10.1111/j.1538-7836.2009.03588.x Giannakopoulos, 2013, The pathogenesis of the antiphospholipid syndrome, N Engl J Med, 368, 1033, 10.1056/NEJMra1112830 Pierangeli, 2005, Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia, Arthritis Rheum, 52, 2120, 10.1002/art.21157 Shamonki, 2007, Excessive complement activation is associated with placental injury in patients with antiphospholipid antibodies, Am J Obstet Gynecol, 196, 167.e1, 10.1016/j.ajog.2006.10.879 Girardi, 2004, Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation, Nat Med, 10, 1222, 10.1038/nm1121 Holers, 2002, Complement C3 activation is required for antiphospholipid antibody-induced fetal loss, J Exp Med, 195, 211, 10.1084/jem.200116116 Girardi, 2003, Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome, J Clin Invest, 112, 1644, 10.1172/JCI200318817 Davis, 1992, Antiphospholipid antibodies and complement activation in patients with cerebral ischemia, Clin Exp Rheumatol, 10, 455 Wojta, 2002, C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils, Blood, 100, 517, 10.1182/blood.V100.2.517 Wetsel, 1995, Structure, function and cellular expression of complement anaphylatoxin receptors, Curr Opin Immunol, 7, 48, 10.1016/0952-7915(95)80028-X Kondo, 2001, The role of C5a in the development of thrombotic glomerulonephritis in rats, Clin Exp Immunol, 124, 323, 10.1046/j.1365-2249.2001.01513.x Lonze, 2010, Eculizumab and renal transplantation in a patient with CAPS, N Engl J Med, 362, 1744, 10.1056/NEJMc0910965 Shapira, 2012, Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab, Arthritis Rheum, 64, 2719, 10.1002/art.34440 Zuily, 2013, Valvular heart disease in antiphospholipid syndrome, Curr Rheumatol Rep, 15, 320, 10.1007/s11926-013-0320-8 Hojnik, 1996, Heart valve involvement (Libman-Sacks endocarditis) in the antiphospholipid syndrome, Circulation, 93, 1579, 10.1161/01.CIR.93.8.1579 Zuily, 2011, Increased risk for heart valve disease associated with antiphospholipid antibodies in patients with systemic lupus erythematosus: meta-analysis of echocardiographic studies, Circulation, 124, 215, 10.1161/CIRCULATIONAHA.111.028522 Ziporen, 1996, Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves, Lupus, 5, 196, 10.1177/096120339600500306 Blank, 2004, Libman-Sacks endocarditis associated with antiphospholipid syndrome and infection, Thromb Res, 114, 589, 10.1016/j.thromres.2004.06.039 Hernández-Molina, 2013, The role of lupus anticoagulant and triple marker positivity as risk factors for rethrombosis in patients with primary antiphospholipid syndrome, Clin Exp Rheumatol, 31, 382 Pengo, 2010, Clinical course of high-risk patients diagnosed with antiphospholipid syndrome, J Thromb Haemost, 8, 237, 10.1111/j.1538-7836.2009.03674.x Rupa-Matysek, 2014, The relationship between mean platelet volume and thrombosis recurrence in patients diagnosed with antiphospholipid syndrome, Rheumatol Int, 34, 1599, 10.1007/s00296-014-2996-0 Aĭsina, 2014, [Polymorphism of the plasminogen activator inhibitor type 1 gene, plasminogen level and thrombosis in patients with antiphospholipid syndrome], Biomed Khim, 60, 72, 10.18097/pbmc20146001072 Sciascia, 2014, Thrombotic risk assessment in systemic lupus erythematosus: validation of the global antiphospholipid syndrome score in a prospective cohort, Arthritis Care Res (Hoboken), 66, 1915, 10.1002/acr.22388 Sciascia, 2015, The global anti-phospholipid syndrome score in primary APS, Rheumatology (Oxford), 54, 134, 10.1093/rheumatology/keu307 Sciascia, 2014, Thrombotic risk assessment in APS: the Global APS Score (GAPSS), Lupus, 23, 1286, 10.1177/0961203314541317 Matsuzawa, 2015, Prognostic value of flow-mediated vasodilation in brachial artery and fingertip artery for cardiovascular events: a systematic review and meta-analysis, J Am Heart Assoc, 4, e002270, 10.1161/JAHA.115.002270 Ruiz-Irastorza, 2011, Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies, Lupus, 20, 206, 10.1177/0961203310395803 Medina, 2011, Prevalence of metabolic syndrome in primary antiphospholipid syndrome patients, Autoimmun Rev, 10, 214, 10.1016/j.autrev.2010.10.004 Arnaud, 2015, Patient-level analysis of five international cohorts further confirms the efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies, Autoimmun Rev, 14, 192, 10.1016/j.autrev.2014.10.019 Arnaud, 2014, Efficacy of aspirin for the primary prevention of thrombosis in patients with antiphospholipid antibodies: an international and collaborative meta-analysis, Autoimmun Rev, 13, 281, 10.1016/j.autrev.2013.10.014 Cuadrado, 2014, Low-dose aspirin vs low-dose aspirin plus low-intensity warfarin in thromboprophylaxis: a prospective, multicentre, randomized, open, controlled trial in patients positive for antiphospholipid antibodies (ALIWAPAS), Rheumatology (Oxford), 53, 275, 10.1093/rheumatology/ket313 Edwards, 1997, Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice, Circulation, 96, 4380, 10.1161/01.CIR.96.12.4380 Espinola, 2002, Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies, Thromb Haemost, 87, 518, 10.1055/s-0037-1613033 Loudon, 1988, Hydroxychloroquine and postoperative thromboembolism after total hip replacement, Am J Med, 85, 57, 10.1016/0002-9343(88)90364-6 Ruiz-Irastorza, 2010, Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review, Ann Rheum Dis, 69, 20, 10.1136/ard.2008.101766 Erkan, 2002, A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome, Rheumatology (Oxford), 41, 924, 10.1093/rheumatology/41.8.924 Sciascia, 2016, The efficacy of hydroxychloroquine in altering pregnancy outcome in women with antiphospholipid antibodies. Evidence and clinical judgment, Thromb Haemost, 115, 285, 10.1160/th15-06-0491 Lim, 2006, Management of antiphospholipid antibody syndrome: a systematic review, JAMA, 295, 1050, 10.1001/jama.295.9.1050 Ruiz-Irastorza, 2007, A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies, Arthritis Rheum, 57, 1487, 10.1002/art.23109 Levine, 2004, Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke, JAMA, 291, 576, 10.1001/jama.291.5.576 Okuma, 2009, Comparison between single antiplatelet therapy and combination of antiplatelet and anticoagulation therapy for secondary prevention in ischemic stroke patients with antiphospholipid syndrome, Int J Med Sci, 7, 15 Khamashta, 1995, The management of thrombosis in the antiphospholipid-antibody syndrome, N Engl J Med, 332, 993, 10.1056/NEJM199504133321504 Schulman, 1998, Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy, Am J Med, 104, 332, 10.1016/S0002-9343(98)00060-6 Yazici A, Unlu O, Erkan D. A systematic review of direct oral anticoagulant use in antiphospholipid syndrome. Presented at: 15th International Congress on Antiphospholipid Antibodies; September 21–24, 2016; Istanbul, Turkey (Relocated to North Cyprus). Unlu O, Cohen H, Cuadrado M, et al. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Analysis: direct oral anticoagulant use among antiphospholipid syndrome patients. Presented at: 15th International Congress on Antiphospholipid Antibodies; September 21–24, 2016; Istanbul, Turkey (Relocated to North Cyprus). Cohen, 2016, Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial, Lancet Haematol, 3, e426, 10.1016/S2352-3026(16)30079-5 Erkan, 2014, 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends, Autoimmun Rev, 13, 685, 10.1016/j.autrev.2014.01.053 Holtan, 2006, Use of fondaparinux in a patient with antiphospholipid antibody syndrome and heparin-associated thrombocytopenia, J Thromb Haemost, 4, 1632, 10.1111/j.1538-7836.2006.01961.x Pendleton, 2006, Argatroban dosing of patients with heparin-induced thrombocytopenia and an elevated aPTT due to antiphospholipid antibody syndrome, Ann Pharmacother, 40, 972, 10.1345/aph.1G319 Danesh, 2003, Immunomodulatory effects of HMG-CoA reductase inhibitors, Arch Immunol Ther Exp (Warsz), 51, 139 Meroni, 2001, Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype, Arthritis Rheum, 44, 2870, 10.1002/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y Ferrara, 2004, Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid antibodies on endothelial cells, J Thromb Haemost, 2, 1558, 10.1111/j.1538-7836.2004.00896.x Erkan, 2014, A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients, Ann Rheum Dis, 73, 1176, 10.1136/annrheumdis-2013-203622 Ahya, 2011, Increased risk of venous thromboembolism with a sirolimus-based immunosuppression regimen in lung transplantation, J Heart Lung Transplant, 30, 175, 10.1016/j.healun.2010.08.010 Austin, 2008, The VWF/ADAMTS13 axis in the antiphospholipid syndrome: ADAMTS13 antibodies and ADAMTS13 dysfunction, Br J Haematol, 141, 536, 10.1111/j.1365-2141.2008.07074.x Hidalgo, 2014, Inhibition of the mTORC pathway in the antiphospholipid syndrome, N Engl J Med, 371, 1554 Verhave, 2014, The risk of thromboembolic events in kidney transplant patients, Kidney Int, 85, 1454, 10.1038/ki.2013.536 Berman, 2013, Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab, Autoimmun Rev, 12, 1085, 10.1016/j.autrev.2013.05.004 Wang, 2016, Rituximab usage in systemic lupus erythematosus-associated antiphospholipid syndrome: a single-center experience, Semin Arthritis Rheum, 46, 102, 10.1016/j.semarthrit.2016.02.002 Bakshi, 2013, Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome, Lupus, 22, 865, 10.1177/0961203313491023 Erkan, 2013, A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome, Arthritis Rheum, 65, 464, 10.1002/art.37759 Canaud, 2013, Eculizumab improves posttransplant thrombotic microangiopathy due to antiphospholipid syndrome recurrence but fails to prevent chronic vascular changes, Am J Transplant, 13, 2179, 10.1111/ajt.12319 Sciascia, 2012, Prevention of thrombosis relapse in antiphospholipid syndrome patients refractory to conventional therapy using intravenous immunoglobulin, Clin Exp Rheumatol, 30, 409 Sherer, 2000, Intravenous immunoglobulin therapy of antiphospholipid syndrome, Rheumatology (Oxford), 39, 421, 10.1093/rheumatology/39.4.421 Cervera, 2014, 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome, Autoimmun Rev, 13, 699, 10.1016/j.autrev.2014.03.002 Bates, 2012, VTE, thrombophilia, antithrombotic therapy, and pregnancy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines, Chest, 141, e691S, 10.1378/chest.11-2300 de Jesus, 2014, 14th International Congress on Antiphospholipid Antibodies task force report on obstetric antiphospholipid syndrome, Autoimmun Rev, 13, 795, 10.1016/j.autrev.2014.02.003 Kutteh, 1996, Antiphospholipid antibody-associated recurrent pregnancy loss: treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone, Am J Obstet Gynecol, 174, 1584, 10.1016/S0002-9378(96)70610-5 Rai, 1997, Randomised controlled trial of aspirin and aspirin plus heparin in pregnant women with recurrent miscarriage associated with phospholipid antibodies (or antiphospholipid antibodies), BMJ, 314, 253, 10.1136/bmj.314.7076.253 Farquharson, 2002, Antiphospholipid syndrome in pregnancy: a randomized, controlled trial of treatment, Obstet Gynecol, 100, 408, 10.1097/00006250-200212000-00032 Laskin, 2009, Low molecular weight heparin and aspirin for recurrent pregnancy loss: results from the randomized, controlled HepASA Trial, J Rheumatol, 36, 279, 10.3899/jrheum.080763 Ioannou, 2007, Binding of antiphospholipid antibodies to discontinuous epitopes on domain I of human β2-glycoprotein I: mutation studies including residues R39 to R43, Arthritis Rheum, 56, 280, 10.1002/art.22306 Ioannou, 2009, In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of β2-glycoprotein I: proof of concept, J Thromb Haemost, 7, 833, 10.1111/j.1538-7836.2009.03316.x Ostertag, 2006, A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice, Lupus, 15, 358, 10.1191/0961203306lu2315oa Kolyada, 2014, Inhibition of thrombotic properties of persistent autoimmune anti-β2GPI antibodies in the mouse model of antiphospholipid syndrome, Blood, 123, 1090, 10.1182/blood-2013-08-520882